The following list of drugs, which are currently on the CDF list, will be re-evaluated at the next meeting of the national CDF panel on 15 and 16 December 2014. The re-evaluation of existing drugs, as well as the evaluation of a number of new drugs, will assess the clinical benefit delivered in treating a patient with a drug, in relation to the cost of that drug.
You are here
drugs to be assessed at the next meeting of the national CDF panel – December 2014
And we're back to the dichotomy of high drug pricing funding the development of other drugs. I know the panel is looking at efficacy vs cost vs additional quality time, but it all comes down to price. If the meds were as cheap as paracetamol nobody would care.
A negative finding in the case of dasatinib might actually prompt BMS to bring their pricing in line with tasigna, thereby opening the door for it to be a standard approved therapy in the longer term.
I sincerely hope that all the TKIs are shown to represent good value for money.
Fingers crossed for successful outcomes.
C
Thanks Chris.
I just want to stress that treatment of chronic or accelerated phase CML using dasatinib will NOT be included in the re-evaluation exercise. Ponatinib will NOT be re-evaluated for the treatment of patients with the T315i mutation.
Clinicians can therefore continue to make applications to the CDF for CML patients who meet the above criteria.
I would also stress again that any patient currently receiving treatment with a drug on the CDF will be able to continue treatment indefinitely with that drug unless their clinical situation changes.
Finally, decisions following the CDF re-evaluation exercise are to be announced on 2nd January, in private, to the pharma companies concerned, with further 'public' meetings planned for the 15th and 16th January, although it is uncertain what definition of ‘public‘ will be used.
It is widely expected that following the 2nd January meeting, companies with drugs that emerge from the re-evaluation exercise with a recognition that although they are clinically effective they fail on the new cost test, will be granted some further time to offer discounts in order to remain within the CDF.
How much time such companies will be given for this is not yet clear, neither is it clear how new CDF applications made after January 2nd, but before the final decisions, will be treated.
But the important thing here is that dasatinib, for chronic phase CML, is not included in the re-evaluation list, so it will remain available, as will ponatinib for T315i mutation status. Bosutinib will be re-evaluated for its current indications.
David